InVivoMAb anti-mouse CD172a (SIRPalpha)

Yanagita T, Murata Y, Tanaka D, et al. Anti-SIRPα antibodies as a potential new tool for cancer immunotherapy. JCI Insight. 2017,2(1):e89140. doi: 10.1172/jci.insight.89140

Zen K, Guo Y, Bian Z, et al. Inflammation-induced proteolytic processing of the SIRPα cytoplasmic ITIM in neutrophils propagates a proinflammatory state. Nat Commun. 2013,4:2436. doi: 10.1038/ncomms3436

Koskinen C, Persson E, Baldock P, et al. Lack of CD47 impairs bone cell differentiation and results in an osteopenic phenotype in vivo due to impaired signal regulatory protein α (SIRPα) signaling. J Biol Chem. 2013,288(41):29333-44. doi: 10.1074/jbc.M113.494591

Teraoka Y, Ide K, Morimoto H, et al. Expression of recipient CD47 on rat insulinoma cell xenografts prevents macrophage-mediated rejection through SIRPα inhibitory signaling in mice. PLoS One. 2013,8(3):e58359. doi: 10.1371/journal.pone.0058359

Lundberg P, Koskinen C, Baldock PA, et al. Osteoclast formation is strongly reduced both in vivo and in vitro in the absence of CD47/SIRPalpha-interaction. Biochem Biophys Res Commun. 2007,352(2):444-8.

Oldenborg PA, Gresham HD, Lindberg FP. CD47-signal regulatory protein alpha (SIRPalpha) regulates Fcgamma and complement receptor-mediated phagocytosis. J Exp Med. 2001,193(7):855-62.